A Multicenter Pilot Study of a Bronchial Valve for the Treatment of Severe Emphysema

D.H. Sterman\textsuperscript{a}  A.C. Mehta\textsuperscript{b}  D.E. Wood\textsuperscript{c}  P.N. Mathur\textsuperscript{d}  R.J. McKenna, Jr.\textsuperscript{e}  D.E. Ost\textsuperscript{f}  J.D. Truwit\textsuperscript{g}  P. Diaz\textsuperscript{h}  M.M. Wahidi\textsuperscript{i}  R. Cerfolio\textsuperscript{j}  R. Maxfield\textsuperscript{k}  A.I. Musani\textsuperscript{a}  T. Gildea\textsuperscript{b}  F. Sheski\textsuperscript{c}  M. Machuzak\textsuperscript{a,b}  A.R. Haas\textsuperscript{a}  H.X. Gonzalez\textsuperscript{l}  S.C. Springmeyer\textsuperscript{l} for the IBV Valve US Pilot Trial Research Team

\textsuperscript{a} University of Pennsylvania Medical Center, Philadelphia, Pa.  \textsuperscript{b} Cleveland Clinic, Cleveland, Ohio  \textsuperscript{c} University of Washington, Seattle, Wash.  \textsuperscript{d} Indiana University Hospital, Indianapolis, Ind.  \textsuperscript{e} Cedars-Sinai Medical Center, Los Angeles, Calif.  \textsuperscript{f} North Shore University Hospital, Manhasset, N.Y.  \textsuperscript{g} University of Virginia Health System, Charlottesville, Va.  \textsuperscript{h} Ohio State University, Columbus, Ohio  \textsuperscript{i} Duke University Medical Center, Durham, N.C.  \textsuperscript{j} University of Alabama at Birmingham, Birmingham, Ala.  \textsuperscript{k} Columbia University Medical Center, New York, N.Y.  \textsuperscript{l} Spiration, Inc., Redmond, Wash., USA

Abstract

Background: Chronic obstructive pulmonary disease (COPD) affects millions of people and has limited treatment options. Surgical treatments for severe COPD with emphysema are effective for highly selected patients. A minimally invasive method for treating emphysema could decrease morbidity and increase acceptance by patients. Objective: To study the safety and effectiveness of the IBV\textsuperscript{\textregistered} Valve for the treatment of severe emphysema. Methods: A multicenter study treated 91 patients with severe obstruction, hyperinflation and upper lobe (UL)-predominant emphysema with 609 bronchial valves placed bilaterally into ULs. Results: Valves were placed in desired airways with 99.7% technical success and no migration or erosion. There were no procedure-related deaths and 30-day morbidity and mortality were 5.5 and 1.1%, respectively. Pneumothorax was the most frequent serious device-related complication and primarily occurred when all segments of a lobe, especially the left UL, were occluded. Highly significant health-related quality of life (HRQL) improvement (–8.2 \pm 16.2, mean \pm SD change at 6 months) was observed. HRQL improvement was associated with a decreased volume (mean –294 \pm 427 ml, p = 0.007) in the treated lobes without visible atelectasis. FEV\textsubscript{1}, exercise tests, and total lung volume were not changed but there was a proportional shift, a redirection of inspired volume to the untreated lobes. Combined with perfusion scan changes, this suggests that there is improved ventilation and perfusion matching in non-UL lung parenchyma. Conclusion: Bronchial valve treatment of emphysema has multiple mechanisms of action and acceptable safety, and significantly improves quality of life for the majority of patients.

Copyright © 2009 S. Karger AG, Basel

Key Words

Bronchial valve \cdot Bronchoscopic treatment of emphysema \cdot Chronic obstructive pulmonary disease \cdot Emphysema \cdot Endobronchial lung volume reduction \cdot Valve placement

Received: August 3, 2009  Accepted after revision: October 5, 2009  Published online: November 17, 2009

Funded by Spiration, Inc., Redmond, Wash., USA.
Introduction

Chronic obstructive pulmonary disease (COPD) affects over 10 million people in the United States and 280 million in the world, with an estimated prevalence of 7–9% [1, 2]. In addition, patients underestimate the magnitude of their limitations and thus COPD remains largely underdiagnosed [2]. The airflow limitation of COPD is by definition only partially reversible, so using airflow improvement to assess a treatment response has led to undeserved nihilism regarding treatment [3].

Patients with COPD should be comprehensively evaluated in order to individualize therapy and determine the degree and pattern of their emphysema [4]. It is now known that smoking cessation, oxygen treatment, lung volume reduction surgery (LVRS), and noninvasive ventilation for severe exacerbations have a positive impact on mortality in COPD [3]. Surgical options for the treatment of emphysema – lung transplantation, bullectomy, and LVRS – are applicable to only a limited patient population. In fact, the National Emphysema Treatment Trial (NETT) evaluated 3,777 patients with severe COPD to enroll 1,218 patients for LVRS [5]. The NETT showed that LVRS significantly improves survival, in addition to quality of life and exercise capacity [6], but after exclusion of a high-risk group, LVRS was associated with a 5% postoperative mortality rate, and a 20 and 30% incidence of major pulmonary and cardiac morbidity, respectively [7]. For these reasons, LVRS is not being utilized to expected levels [8].

In attempt to achieve the physiologic benefits of LVRS with less morbidity and mortality, multiple minimally invasive investigative approaches for advanced emphysema have been initiated in the past decade. For heterogeneous emphysema, these approaches include bronchoscopic insertion of endobronchial blockers [9] or bronchial valves [10, 11] to promote absorption atelectasis and lung volume reduction, and injection of fibrin polymer into emphysematous lung parenchyma to induce tissue fibrosis with contraction of hyperinflated target lung zones [12]. Alternatively, for patients with homogeneous emphysema, another approach has been to reduce hyperinflation by creating stented transbronchial pathways between cartilaginous airways and emphysematous parenchyma [13]. None of these approaches have been approved in the United States for treatment of patients with advanced COPD.

The Spiration IBV® Valve is an umbrella-shaped bronchial valve that is placed via a plastic delivery catheter introduced through the working channel of a flexible bronchoscope. The IBV Valve System has US Food and Drug Administration (FDA) humanitarian device approval for use with selected prolonged postoperative air leaks [14] and has received market clearance in Europe through CE mark for the treatment of diseased and damaged lung. The valve limits airflow into targeted Airways distal to the valve, but allows egress of trapped air and secretions. Previous publications described the preliminary data from the initial 30 patients enrolled in this pilot study [15], and part of the data have been published in summary form combined with an additional 7 patients treated at international sites [16]. Another publication has reported the quantitative computed tomography (QCT) results in the subset of patients with QCT [17]. We report here the final results from a pilot multicenter experience in the United States for bilateral treatment of severe heterogeneous upper-lobe (UL)-predominant emphysema.
ited airway penetration while the 6 proximal struts hold the membrane against the airway wall. The valve is easily compressed to expand and contract with breathing and allow proximal air and secretion flow. This ease of compression also results in gentle pressure on the mucosa. A central rod facilitates grasping with forceps for removal if necessary.

Two delivery systems, ‘direct load’ and ‘catheter,’ were developed for use and have been described [15]. In the catheter system, the valve was compressed into a catheter which can pass through a ≥2.6-mm channel in a flexible bronchoscope for placement into the desired bronchi. With catheter delivery the valve is positioned at the desired location and then the valve is unsheathed. The catheter method was preferred and was the only method used in the last third of the patients enrolled. Multiple valve sizes were available for different-size airways; 5-, 6-, and 7-mm diameter (uncompressed) valves were used throughout the trial. Four-mm valves were available early in the study and 9-mm valves were available late in the study. Airways were sized with a calibrated balloon catheter using standardized visual assessment.

Bronchoscopy was performed through an endotracheal tube or a rigid bronchoscope with local anesthesia and sedation or general anesthesia. Bilateral UL bronchial valve placement has been described previously (see online supplementary videos, www.karger.com/doi/10.1159/000259318) [15]. Given that enrolled patients had UL-predominant emphysema, both ULs were treated. Midway through the trial, adding treatment of the lingular segments of the left UL was allowed at the discretion of the investigator. Treatment of the lingular segments was again excluded for the last third of the trial. No segments in the middle or lower lobes were treated. After valve placement and visual inspection, patients were extubated and moved to the recovery area. In-hospital observation was required for a minimum of 2 nights at the initiation of the study, but then was changed to 1 night. Standard outpatient COPD medical regimens and management were continued during the study. Chest radiography was performed immediately following the procedure and on each day of hospitalization to confirm proper valve position and to assess for focal atelectasis, pneumothorax, and postoperative infiltrates.

Follow-Up

After leaving the hospital, patients were asked to keep a medical diary and record of any symptoms or changes in medical condition. The patients were evaluated within 1–2 weeks with chest radiography, resting oxyhemoglobin saturation, and history and physical examination. One month after the procedure, patients returned for an office visit with scheduled testing. During the initial 2/3 of the trial, a second bronchoscopy was required to inspect the valves and to allow added valve treatment as per investigator discretion. The added bronchoscopies were found to be of no additional clinical benefit, and were discontinued. Patients returned at 3, 6, and 12 months for outpatient visits with testing including a chest radiograph to ensure valve position, as well as a thorough follow-up medical history to assess for interval AEs.

Outcome Measures

In this pilot study, the primary outcome measure was safety, evaluated as the rate of observed migration, erosion, or infection associated with the IBV Valve during the first 3 months after placement. Other protocol-defined safety measures included COPD exacerbations, pneumothorax requiring chest tube for >7 days, hospital length of stay beyond protocol-allowed 3 days, persistent cough, bronchitis or pneumonia, respiratory failure requiring mechanical ventilation >24 h, hemoptysis requiring intervention, and death.

The secondary endpoint was an estimate of effectiveness. Three variables were used as pilot study efficacy measures: (1) 15% increase in FEV₁; (2) 15% increase in 6-min walk distance (6MWT), and (3) improvement in 4 points on the St. George’s Respiratory Questionnaire (SGRQ). Other predetermined potential measures of efficacy included decrease in oxygen supplementation requirements, improvement in Medical Outcome Study Short-Form Health Survey (SF-36) scores, and improvement in the modified Medical Research Council dyspnea score. Questionnaires were completed during periods of clinical stability as much as possible.

Quality of Life

Health-related quality of life (HRQL) was measured with standardized and validated questionnaires. The SGRQ 2.1-English USA version was used for disease-specific measurement and the SF-36 V2™ Health Survey for general health. These questionnaires were selected because of scientific acceptance and widespread use, and to allow comparison to other therapy. The SGRQ, assessed over a period of 4–12 months, has 3 components – activity, impact, and symptoms – and includes questions about breathlessness, cough, and sputum. The score range is from 0 to 100, with higher scores indicating worsening health status. The SF-36 has questions about general health with a 4-week recollection period, and has 8 scales and 2 summary measures: physical and mental health. The administration and scoring of both was done following instructions and manual guides.

Pulmonary Function Testing and Exercise Testing

Pulmonary function testing was done in accordance with American Thoracic Society/European Respiratory Society guidelines and included spirometry before/after bronchodilators, lung volumes by body plethysmography, and a diffusion study. In addition, a metronome-paced breathing test was added during the last third of the study as a simple measure of dynamic hyperinflation [18]. A pacing rate of 30 breaths/min was used without controlling inspiratory or expiratory times.

Exercise testing included testing of walking and cycle ergometry. The 6MWT distances were measured at baseline and at follow-up visits in accordance with American Thoracic Society guidelines. When supplemental oxygen was needed, the flow rate was titrated at each test, as done in the NETT for the first 2/3 of the pilot study [19]. For the last third of the trial, the flow rate was initially determined by titration and held constant for follow-up testing.

Cycle ergometry was initially performed with the NETT method of determining maximum watts using supplemental oxygen in all patients [19]. During the last third of the trial, oxygen was used if prescribed for exercise and an initial test was performed to determine maximum exercise. Then constant load testing at 65% of maximum was repeated 2 or 3 times to establish a baseline value and was used for follow-up testing. It was planned to measure sequential inspiratory capacity values during cycle testing, but this additional testing was beyond the capabilities of the patients and technicians at the clinical laboratories and was not pursued.
Lung Perfusion Scans
Radionuclide scans of the lungs were obtained at baseline and 1–3 months after valve placement to confirm UL predominance and for targeting of treatment locations. The perfusion ratio in the upper regions of the lungs to that in the lower regions was quantified. To determine the ratio, each lung is divided into three zones, and a percentage of total perfusion is assigned to each zone. The ratio is calculated as the sum of the percentages assigned to the two upper zones divided by the sum of the percentages assigned to the four middle and lower zones [5].

Quantitative Computer Tomography
Details about QCT, the methods used, and results have been published [17]. In brief, at the start of the trial, CT imaging was performed at baseline to determine eligibility and consider treatment locations. A second CT was obtained after 1 month and before the second bronchoscopy to provide additional information for treatment planning. To determine the volumes of treated and untreated lobes with QCT, these existing CT scans were obtained when possible and then subsequent scans were done with methodology conducive to QCT measurements. The protocol was revised for the last third of the trial to add CT scans at 6 months when possible for already enrolled patients and to prospectively perform CT scans at baseline and 3 months for new patients.

QCT analyses were performed at the University of British Columbia with customized software (Emphylx). Each lung was manually segmented by determining the fissures separating the UL. The UL volume was subtracted from the total lung volume for the non-UL volume. All QCT volumes presented are the combined densities for the total volume.

Statistics
Descriptive data are expressed as means ± SD or medians. Categorical data are expressed as counts and proportions. Mean scores before and after valve placements were compared using Wilcoxon signed rank test. p < 0.05 was considered statistically significant, and adjustment for multiple tests was not performed. Device-related AEs are those considered definitely or probably device-related unless otherwise specified. Spiration (Inc.) assisted in data collection and collation and provided an independent consultant for statistical analysis.

Results
Enrollment and Baseline Characteristics
This trial enrolled a total of 91 patients at 11 sites in the United States between January 2004 and August 2006. There were a slightly greater proportion of males than females (56 vs. 44%), and the mean age was 64.9 years (SD 8.2, range 42–79 years). Baseline physiological and HRQL characteristics for the overall patient population are summarized in table 1.

Patient Accountability
All patients enrolled underwent bronchoscopic placement of IBV Valves on study day 0 (operative day). No patients were lost to follow-up and accountability is shown in table 2. The expected follow-up ranged between 94 and 100% for the 4 visits. During the 12-month study, there were 7 patient withdrawals within 6 months and 19 more by 12 months. Except for 1 patient that withdrew consent and 1 that relocated, the withdrawals within 6 months were associated with an AE. In contrast, the withdrawals after 6 months were primarily in patients that had not felt improvement, except for 5 patients who withdrew because of an AE. Two withdrawals were after a diagnosis of lung cancer. The 3 deaths associated with pneumothorax are discussed below and the other 3 deaths

Table 1. Baseline data

<table>
<thead>
<tr>
<th></th>
<th>Means ± SD</th>
<th>n</th>
<th>Percent predicted (means ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1, liters</td>
<td>0.87 ± 0.25</td>
<td>91</td>
<td>30.64 ± 7.85</td>
</tr>
<tr>
<td>FVC, liters</td>
<td>2.74 ± 0.81</td>
<td>91</td>
<td>74.38 ± 14.84</td>
</tr>
<tr>
<td>TLC, liters</td>
<td>7.57 ± 1.42</td>
<td>90</td>
<td>129.19 ± 18.3</td>
</tr>
<tr>
<td>RV, liters</td>
<td>4.74 ± 1.06</td>
<td>90</td>
<td>221.47 ± 49.35</td>
</tr>
<tr>
<td>DLCO</td>
<td>9.54 ± 3.45</td>
<td>89</td>
<td>38.57 ± 11.94</td>
</tr>
<tr>
<td>PaO2</td>
<td>68.29 ± 9.05</td>
<td>89</td>
<td>–</td>
</tr>
<tr>
<td>PaCO2</td>
<td>40.45 ± 4.96</td>
<td>91</td>
<td>–</td>
</tr>
<tr>
<td>6MWD, feet</td>
<td>1,108 ± 313</td>
<td>91</td>
<td>–</td>
</tr>
<tr>
<td>Max. work, W</td>
<td>41.28 ± 23.08</td>
<td>52</td>
<td>–</td>
</tr>
<tr>
<td>SF-36 PF</td>
<td>27.50 ± 17.13</td>
<td>90</td>
<td>–</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>33.15 ± 6.17</td>
<td>88</td>
<td>–</td>
</tr>
<tr>
<td>SGRQ: total score</td>
<td>57.27 ± 12.71</td>
<td>88</td>
<td>–</td>
</tr>
</tbody>
</table>

n = Number of patients; PF = physical function; PCS = physical component summary.

Table 2. Patient enrollment and accountability at valve placement and months 1–12 (M1–M12)

<table>
<thead>
<tr>
<th></th>
<th>Patients, n</th>
<th>M1</th>
<th>M3</th>
<th>M6</th>
<th>M12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intent-to-treat</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>91</td>
</tr>
<tr>
<td>Deaths1</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Withdrawal1</td>
<td>0</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>26</td>
</tr>
<tr>
<td>Expected patients</td>
<td>91</td>
<td>86</td>
<td>84</td>
<td>80</td>
<td>59</td>
</tr>
<tr>
<td>Actual patients</td>
<td>91</td>
<td>83</td>
<td>81</td>
<td>75</td>
<td>59</td>
</tr>
<tr>
<td>Follow-up, %</td>
<td>100</td>
<td>97</td>
<td>96</td>
<td>94</td>
<td>100</td>
</tr>
</tbody>
</table>

1 These values are cumulative across time.
were from sudden cardiac death, disease progression, and a non-study procedure complication.

Procedural Results

The mean bronchoscopy (not including preparation or anesthesia) time was 58.9 min ($\pm 31.0$, range 15–187). The airways treated included 482 segmental airways (75%) and 157 subsegmental airways (25%). When a single valve was used to treat 2 segments, it was counted as 2 segments treated. There were 3 instances where a 9-mm valve was used to treat 3 segments (once the right UL), and twice to treat all 5 segments of the left UL. Target locations were successfully treated with valves in 609 of 611 airways (99.7% success), except for the left UL apical segment in 2 patients.

Patients were typically discharged from the hospital on the day after treatment. The median length of stay was 1 day. The mean length of hospital stay was 2.45 days, with a range of 1–33 days (SD 4.72).

A total of 609 valves were implanted in the 91 patients during the treatment phase. Valves were provided in 5 sizes: the 7-mm size was used for 55% (335 valves), the 6-mm for 26.8%, the 9-mm for 13.6%, and the 5-mm size for 4.4% of valve placements. Only one 4-mm valve was implanted throughout the entire pilot study.

A mean of 6.7 valves and median of 6 valves per patient were in place at the completion of treatment procedures (range 3–11 valves). All devices were identified by chest radiography throughout the 12-month study.

Bilateral UL airways were treated in 88 patients. Three patients had unilateral treatment allowed because there was preexisting disease with volume loss in the contralateral UL. Additional treatment of the 2 segments of the lingula of the left UL, in addition to the remainder of the left UL, was performed in 17 patients. The direct load system was used for 17.9% (109/609) of the implants. The catheter system was used for 82.1% (500/609) of the implants.

Health-Related Quality of Life Measures

The HRQL data show strong, significant, and durable improvements in both general and disease-related quality of life associated with IBV Valve treatment (table 3) with the mean changes in SGRQ, the proportion of patients with at least a 4-point improvement in SGRQ, and in the proportion of patients with at least a 10-point change in SF-36 physical function. A clinically significant gain in SGRQ was seen in 51% of the patients at 1 month. This responder rate increased to 53% at 3 months, 55% at 6 months, and 57% at 12 months. At all times the SGRQ changes were statistically significant along with significant improvements in physical function as assessed by the SF-36 at 6 and 12 months.

Regional Lung Volume Changes Measured by QCT

The impact of treatment on regional lung volume measured by QCT scans are detailed in table 4 (volume changes compared to baseline) and table 5. UL treatment resulted in a significant decrease in lung volume, almost 300 ml, at each time point; in 87% of the patients lung volume was decreased at 6 months. In addition, 75% of the patients experienced an increase in non-UL volume at 1 month; 84% demonstrated this gain at 3 months and 93% at 6 months. These volume changes are highly correlated (Spearman’s $-0.473$, $p = 0.002$). In addition, using a definition for a QCT response of $\geq 10\%$ increase in non-UL volume with any decrease in UL volume, there is a significant correlation between QCT response and HRQL response ($p < 0.01$) [17].

Regional Perfusion Measured by Lung Perfusion Scans

The lung perfusion scans showed a baseline decrease in upper-zone perfusion, and after bronchial valve placement there was a further reduction in UL perfusion indicating a shift to the lower zones. At baseline, the mean $\pm$
Table 4. Regional volume changes and proportion changing

<table>
<thead>
<tr>
<th></th>
<th>1 month after treatment</th>
<th>3 months after treatment</th>
<th>6 months after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UL volume</strong></td>
<td>(n = 32)</td>
<td>(n = 32)</td>
<td>(n = 15)</td>
</tr>
<tr>
<td>Change compared to baseline, ml</td>
<td>-260 ± 407 (p &lt; 0.001)</td>
<td>-269 ± 378 (p &lt; 0.001)</td>
<td>-294 ± 427 (p = 0.007)</td>
</tr>
<tr>
<td>Patients with decreases in volume, %</td>
<td>81.3%</td>
<td>81.3%</td>
<td>86.7%</td>
</tr>
<tr>
<td><strong>Non-UL volume</strong></td>
<td>(n = 32)</td>
<td>(n = 32)</td>
<td>(n = 15)</td>
</tr>
<tr>
<td>Change compared to baseline, ml</td>
<td>259 ± 428 (p = 0.001)</td>
<td>248 ± 326 (p &lt; 0.001)</td>
<td>375 ± 400 (p = 0.001)</td>
</tr>
<tr>
<td>Patients with increases in volume, %</td>
<td>75.0%</td>
<td>84.4%</td>
<td>93.3%</td>
</tr>
</tbody>
</table>

Table 5. Lung function, gas exchange, exercise tolerance, dyspnea, and health status before and after valve placement

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1 month</th>
<th>3 months</th>
<th>6 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁, liters</td>
<td>0.87 ± 0.25 (91)</td>
<td>0.85 ± 0.25 (83)</td>
<td>0.83 ± 0.26 (79)</td>
<td>0.83 ± 0.29 (71)</td>
<td>0.85 ± 0.33 (53)</td>
</tr>
<tr>
<td>TLC, liters</td>
<td>7.57 ± 1.42 (90)</td>
<td>7.53 ± 1.47 (83)</td>
<td>7.66 ± 1.47 (79)</td>
<td>7.58 ± 1.47 (70)</td>
<td>7.53 ± 1.62 (52)</td>
</tr>
<tr>
<td>RV, liters</td>
<td>4.74 ± 1.06 (90)</td>
<td>4.77 ± 1.12 (83)</td>
<td>5.00 ± 1.16 (79)</td>
<td>4.89 ± 1.17 (70)</td>
<td>4.71 ± 1.27 (52)</td>
</tr>
<tr>
<td>DLCO</td>
<td>9.54 ± 3.45 (89)</td>
<td>9.81 ± 3.66 (82)</td>
<td>9.57 ± 3.60 (79)</td>
<td>9.60 ± 3.51 (70)</td>
<td>9.43 ± 3.14 (51)</td>
</tr>
<tr>
<td>PaO₂</td>
<td>68.29 ± 9.05 (89)</td>
<td>68.27 ± 9.85 (81)</td>
<td>68.84 ± 10.40 (75)</td>
<td>68.92 ± 10.83 (63)</td>
<td>68.84 ± 11.23 (48)</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>40.45 ± 4.96 (91)</td>
<td>40.58 ± 5.69 (81)</td>
<td>41.44 ± 5.43 (75)</td>
<td>41.82 ± 6.36 (64)</td>
<td>41.25 ± 6.10 (48)</td>
</tr>
<tr>
<td>Prescribed O₂, l/min</td>
<td>1.08 ± 1.34 (91)</td>
<td>1.21 ± 1.22 (82)</td>
<td>1.12 ± 1.29 (78)</td>
<td>1.01 ± 1.15 (71)</td>
<td>0.83 ± 1.11 (54)</td>
</tr>
<tr>
<td>6MWD, feet</td>
<td>1,108 ± 313 (91)</td>
<td>1,102 ± 323 (80)</td>
<td>1,112 ± 335 (76)</td>
<td>1,151 ± 335 (69)</td>
<td>1,173 ± 303 (49)</td>
</tr>
<tr>
<td>Work¹, W</td>
<td>39 ± 20 (77)</td>
<td>37 ± 24 (51)</td>
<td>41 ± 22 (43)</td>
<td>40 ± 23 (42)</td>
<td>40 ± 23 (29)</td>
</tr>
<tr>
<td>QCT UL, ml</td>
<td>3,379 ± 871 (61)</td>
<td>3,121 ± 827 (32)</td>
<td>3,216 ± 984 (32)</td>
<td>3,035 ± 1254 (15)</td>
<td>ND</td>
</tr>
<tr>
<td>QCT non-UL, ml</td>
<td>3,414 ± 824 (61)</td>
<td>3,696 ± 860 (32)</td>
<td>3,692 ± 975 (32)</td>
<td>3,475 ± 1019 (15)</td>
<td>ND</td>
</tr>
<tr>
<td>MMRC</td>
<td>2.0 ± 0.8 (87)</td>
<td>1.9 ± 0.8 (81)</td>
<td>1.8 ± 0.9 (79)</td>
<td>1.8 ± 1.0 (70)</td>
<td>1.6 ± 0.9 (54)</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>33.15 ± 6.17 (88)</td>
<td>33.80 ± 7.87 (81)</td>
<td>33.49 ± 9.03 (79)</td>
<td>35.00 ± 9.77 (70)</td>
<td>35.37 ± 9.19 (54)</td>
</tr>
<tr>
<td>SF-36 PF</td>
<td>27.5 ± 17.3 (90)</td>
<td>30.94 ± 19.93 (81)</td>
<td>30.44 ± 21.59 (79)</td>
<td>33.88 ± 23.94 (70)</td>
<td>36.63 ± 23.97 (54)</td>
</tr>
<tr>
<td>SGRQ: total</td>
<td>57.27 ± 12.71 (88)</td>
<td>52.90 ± 13.67 (81)</td>
<td>53.06 ± 16.56 (79)</td>
<td>50.05 ± 18.00 (68)</td>
<td>48.53 ± 16.22 (54)</td>
</tr>
<tr>
<td>SGRQ: activity</td>
<td>78.60 ± 13.95 (88)</td>
<td>74.36 ± 17.24 (81)</td>
<td>73.91 ± 19.99 (79)</td>
<td>71.41 ± 22.20 (69)</td>
<td>69.43 ± 21.64 (54)</td>
</tr>
<tr>
<td>SGRQ: impact</td>
<td>42.92 ± 15.71 (89)</td>
<td>37.09 ± 15.10 (81)</td>
<td>38.66 ± 18.28 (79)</td>
<td>34.99 ± 18.01 (70)</td>
<td>33.91 ± 17.06 (54)</td>
</tr>
<tr>
<td>SGRQ: symptom</td>
<td>63.64 ± 17.45 (89)</td>
<td>64.43 ± 18.88 (81)</td>
<td>60.82 ± 20.36 (79)</td>
<td>57.92 ± 21.43 (69)</td>
<td>56.96 ± 20.69 (54)</td>
</tr>
</tbody>
</table>

Means ± SD (n of patients). MMRC = Modified Medical Research Council; PCS = physical component summary; PF = physical function.

¹ The follow-up values are for the patients that did maximum exercise testing throughout the study period.

SD perfusion ratio was 0.26 ± 0.20 (n = 91), compared to 0.20 ± 0.14 (n = 60) and 0.13 ± 0.07 (n = 25) at 1 and 3 months, respectively. Compared to the baseline value, the UL percent perfusion decreases were 6 and 9% further at 1 and 3 months, respectively.

**Pulmonary Function, Arterial Blood Gas, Oxygen Use, Exercise, Questionnaire, and Breathing Test Results**

The results of pulmonary function, arterial blood gas (ABG), oxygen use, exercise tests, and HRQL questionnaires are shown in table 5. In contrast to the significant and sustained improvements in health status and regional lung volumes, there were no significant and sustained changes in lung volumes, airflow rates, oxygen use, or ABG at rest. There was an increase of 43 feet (4%) in the mean 6MWT distance between baseline and 6 months after treatment, but this is not statistically significant, and the mean change per patient was 16 ± 227 feet (p = 0.19).

Cycle ergometry testing did not show improvement in maximum work by cycle ergometry. Likewise, the duration of exercise at a fixed workload was not consistently improved and was −62 ± 252 s (n = 19) at 3 months, −31
± 349 s (n = 14) and +88 ± 366 s (n = 4) at 12 months. Ergometry testing was difficult for these patients and many refused the testing at follow-up. The paced breathing testing results did not show significant changes in the inspiratory capacities at rest or after metronome pacing in the 27 patients tested (data not shown).

**Safety Results**

### Primary Outcome

For the primary outcome measure of the study, there were no occurrences of IBV Valve migration or erosion in any study patient within the entire study period of 12 months. There was one episode each of pneumonia and bacterial bronchitis associated with valves within the first 3 months of implantation, so the rate of observed events for the primary safety objective was 2 of the 84 patients expected for follow-up at 3 months (2.4%).

### Procedure-Related Complications

There were no procedure-related deaths. All events within 3 days of a bronchoscopy procedure were reviewed. There were 8 episodes of dyspnea and wheezing after bronchoscopy that were classified as bronchospasm. One was serious and associated with respiratory failure and myocardial infarction that began the evening after an uneventful procedure [15]. This patient had further episodes of bronchospasm, and therefore proceeded to uncomplicated valve removal on day 21. A second patient had all valves removed on day 3 because the bronchospasm did not resolve. Three additional episodes of bronchospasm resolved promptly after nebulizer treatments and 2 resolved with additional treatment.

Other complications associated with study procedures included: 1 patient who suffered a myocardial infarction on day 3; 3 episodes where valve placements were inadvertently deeper than the desired target locations with resultant injury to the bronchi, and 2 patients with transient hypercapnia (with 1 requiring overnight ventilatory support).

### Protocol-Specified Safety Measures

Other safety measures specified by the protocol are summarized in table 6. These are events that were device-related. Another specified safety measure was a hospitalization >3 days after the initial procedure, which occurred in 9 patients. Cough was considered an AE if it persisted beyond 3 days after the procedure; this occurred in only 1 patient.

**Other Severe or Serious AEs**

The investigators judged that 7 patients had AEs that were serious or severe and definitely device-related. Five of these were episodes of pneumothorax and are discussed in detail below. One had episodes of bronchospasm starting after the procedure and is discussed above. One had a sequence of events that began with bronchitis on day 30, then a COPD exacerbation on day 57, followed by *Pseudomonas* respiratory tract infection on day 74, and finally UL pneumonia on day 333.

**Pneumonia**

There were 6 episodes of pneumonia in an area of valve treatment. None occurred within 3 months of the procedure, 2 were between 3 and 6 months and 4 were 6+ months after treatment. The overall incidence of pneumonia distal to valves within 6 months was 2.2% of subjects or 1.1% of lobes treated (6.6% of subjects or 3.4% of lobes treated within 12 months).

**Pneumothorax**

Three patients had pneumothorax with prolonged air leaks (3.3%) and 2 were among the 3 deaths directly or indirectly related to pneumothorax. One patient died from tension pneumothorax occurring during sleep 4 days after valve placement. The procedure in this patient was uneventful and the chest film after the procedure showed no atelectasis. A patient expired on day 113 from respiratory failure and pneumonia resulting from COPD exacerbation on day 81 and pneumothorax on day 91.

### Table 6. Other protocol-defined safety measures (number of device-related occurrences in 91 patients)

<table>
<thead>
<tr>
<th>Event</th>
<th>Time after procedure</th>
<th>Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumothorax (and air leak &gt;7 days)</td>
<td></td>
<td>&lt;1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-12</td>
</tr>
<tr>
<td>COPD exacerbation</td>
<td></td>
<td>&lt;1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-6</td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td>&lt;1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-6</td>
</tr>
<tr>
<td>Bronchitis or pneumonia in the post-treatment period</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Respiratory failure with mechanical ventilation &gt;24 h</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Bleeding and hemoptysis that requires hospitalization or transfusion</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

1 Bronchitis.
One patient died on day 33 related to respiratory failure and pneumonia after an intra-operative tension pneumothorax on day 20 during placement of a double-lumen endotracheal tube in preparation for surgical repair of a prolonged air leak after pneumothorax with lobar atelectasis which began on day 1.

During the 12-month study, there were a total of 11 patients that experienced pneumothorax (12.1%). This does not include 1 patient that had a pneumothorax following needle aspiration of a nodular density. Five patients underwent chest tube insertion for pneumothorax that occurred in the hospital and 1 patient developed a pneumothorax in hospital which resolved without tube drainage. One patient had the pneumothorax worsen after discharge and then received chest tube treatment. Four patients experienced delayed-onset pneumothorax 4 (2 patients), 9 and 91 days after the procedure.

Analysis of pneumothorax data in this pilot study showed that 5 patients with pneumothorax on the left side had treatment of the lingula in addition to the ULs. Only 17 patients had complete left UL treatment (lingula included) so this was a 29% incidence. The treatment algorithm was subsequently modified to exclude treatment of the lingular segments of the left UL. There were 2 episodes of left pneumothorax after modification of the treatment algorithm, but these were iatrogenic and not device-related.

**Device Removal**

Valve removal was performed (44 valves in 16 patients) for pneumonia, bronchospasm, recurrent COPD exacerbations, or pneumothorax. Valves were removed when there was concern about possible pneumonia in an area near a valve location (6 patients). These removals were 97, 105, 216, 265, 358, and 358 days after device placement. There were 3 valves removed in each of 5 patients and 1 valve was removed in 1 patient for a total of 16 valves removed. A total of 23 valves were removed from 3 patients for persistent or recurrent bronchospasm after the procedure (2 cases on days 3 and 21), and recurrent exacerbations of COPD (1 case on day 377). In 2 cases of pneumothorax with persistent atelectasis and air leak, 5 valves were removed on days 15 and 26.

**Discussion**

The primary outcome measure for this pilot study of bronchoscopic treatment with the IBV Valve was safety based on the incidence of valve migration, erosion, or infection. With no migration or erosion and a rate of associated infection <2.5%, we conclude that this study achieved the primary safety outcome goal.

The secondary endpoint for the study was effectiveness based on FEV1, 6MWT, and SGRQ. The mean SGRQ change exceeded a clinically meaningful [20] 4-point change at all time points and was statistically significant compared to baseline at all time points. This improvement is notable because it was additive to ongoing treatment in patients that have few additional therapeutic options beyond risk reduction, medical therapy, and pulmonary rehabilitation.

HRQL (measured by the SGRQ) is arguably the most appropriate endpoint for palliative treatment. Unlike physiologic or functional tests, the SGRQ was designed to measure multiple mechanisms of improvement simultaneously [21]. Given that bronchial valve treatment positively has multiple mechanisms of action, the SGRQ may be particularly advantageous for assessing bronchial valve treatment of emphysema.

There are at least three mechanisms for improvement with bronchial valve treatment. The original hypothesis was that blocking an airway would cause lobar atelectasis to emulate lung volume reduction (reported by Toma et al. [10] in 2003). The second mechanism is the reduction of dynamic hyperinflation (reported by Hopkinson et al. [22] in 2005). We are disappointed that in a multicenter trial that used clinical laboratories, we were not able to test for dynamic hyperinflation during exercise. The third mechanism is the interlobar shift of ventilation from the treated UL to the untreated lung zones identified by serial QCT as reported in 2008 [17]. The redirection of ventilation combined with the change in perfusion ratios reported here lends support to the concept that the redistribution of ventilation/perfusion results in improved ventilation/perfusion matching, and that this ultimately translated into documented improvements in HRQL. The correlation between QCT changes and HRQL improvements seen in this pilot study supports this hypothesis. Patients may improve with one or more of these mechanisms of action; thus, these mechanisms are not mutually exclusive, although the safety associated with each will be different.

Given the fact that neither FEV1 nor 6MWT results showed significant improvement in this study, it raises the concern that the significant SGRQ improvements seen in this trial could be due to a placebo effect. We think not because the regional lung volume changes found with serial QCT are unlikely to be due to a placebo effect, and these QCT changes correlated highly with the SGRQ improvements [17].
FEV<sub>1</sub> is appropriate for assessment of asthma therapy and measuring the degree of airflow obstruction in COPD. The question is whether FEV<sub>1</sub> is a good measure of treatment effect in studies of severe emphysema where patients have fixed obstruction and those with reversible airflow obstruction are excluded from the study. As with total lung volume measures by body plethysmography, FEV<sub>1</sub> cannot assess a regional effect of treatment, especially with an intervention that blocks about a third of each lung from ventilation. Considering this degree of reduction in ventilation, it is remarkable that the postoperative FEV<sub>1</sub> remained stable, rather than decreasing, implying improvement in expiratory airflow in untreated lobes. In addition, FEV<sub>1</sub> is effort-dependent, has more variability in severe than mild COPD, and, with the loss of elastic recoil in severe emphysema, FEV<sub>1</sub> can be negatively effort-dependent [23, 24], all of which can limit its utility as an outcome measure.

Pulmonary rehabilitation for severe COPD does not change FEV<sub>1</sub> but significantly improves dyspnea, exercise performance, and HRQL [25]. A pharmacotherapy study has shown that improvements in exercise endurance time and exertional dyspnea did not correlate with changes in FEV<sub>1</sub> [26]. Dyspnea is also a better predictor for survival than FEV<sub>1</sub> in severe COPD [27]. Therefore, FEV<sub>1</sub> is not a sensitive indicator at this phase of the disease [28] and this may be the reason that changes in FEV<sub>1</sub> were not observed.

Exercise tests may lack sensitivity and specificity as endpoints in severe COPD. It has been shown that patients with advanced COPD show a greater loss in exercise capacity than in FEV<sub>1</sub> percent predicted [29]. The 6MWT is attractive because of its low complexity, but is considered more a test of endurance, and only has moderate correlation with other outcome variables in COPD such as HRQL [30]. When the 6MWT test is severely reduced it becomes a reliable predictor of mortality in COPD, but this may be due to loss of muscle mass and peripheral muscle dysfunction [31, 32] rather than solely a decrement in respiratory function. In addition, the 6MWT results can be confounded by the use of supplemental oxygen, effort, and practice, and the results can be affected by the function of non-respiratory issues [33], including psychological factors [34]. Even studies of the 6MWT for predicted values vary by up to 30% [33], and >50% of patients with surgery in the NETT had no improvement in the 6MWT [5]. Cycle ergometry is less studied in this patient population because of complexity, expense, and technologist training [33] and, like 6MWT, may be confounded in this severe patient population.

Therefore, the lack of a measured bronchial valve treatment effect on these exercise tests may be due to the inherent limitations of these tests.

The procedure and device safety results deserve more comment. Not surprisingly, advanced age is associated with more procedure complications in patients with severe COPD [16]. Bronchospasm after bronchoscopy is a well-known complication [35]. Pneumothorax and prolonged air leak have been reported as complications with both LVRS and bronchoscopic treatment of emphysema [36, 10]. The development of pneumothorax after bronchoscopic valve treatment is presumably due to tension on adjacent tissue, overexpansion of blebs or bullae, or adhesions when lobar or segmental lung volume reduction occurs, and there is an association between induction of lobar atelectasis and pneumothorax [16]. Therefore, complete or total treatment of all Airways within a single lobe would be expected to be associated with a greater incidence of pneumothorax as a result of decreased intralobar collateral ventilation and greater expected incidence of lobar atelectasis. We observed pneumothorax in 5 of 17 patients when treatment of the lingular segments was added to left UL treatment. Therefore, avoidance of occlusion of every airway of a single lobe may be prudent until there is a proven method to predict which patients are at greatest risk for pneumothorax.

LVRS is an option for select patients with emphysema but has significant morbidity and mortality. In the NETT, 30-day morbidity for major pulmonary and cardiac complications, e.g. mechanical ventilation for >3 days, re-intubation, pulmonary embolism, myocardial infarction, and arrhythmia requiring treatment, was 49.8% [7]. The comparable rate in this trial with bronchial valve treatment was 5.5%. Mortality, due to all causes within 90 days for the non-high-risk surgical cohort in the NETT was 5.8% [5], whereas in this trial it was 3.3%. The HRQL results measured at 6 months by SGRQ with LVRS in the NETT achieved a peak improvement of −11.3 points with 60% of patients responding (−4-point threshold) compared to an improvement of −8.2 points and a 55% responder rate with bronchial valve treatment. This suggests that bronchial valve treatment has a favorable risk/benefit ratio, at least in terms of HRQL, compared to LVRS.

There are limitations to the conclusions from this study. As a pilot trial there was no control group, thus a double-blind, randomized, controlled study is necessary to assess the extent by which the observed changes in HRQL and effort-dependent pulmonary and exercise
tests may be affected by a placebo effect or patient dropout. The regional volume changes demonstrated on QCT are less likely to be impacted by a placebo effect. A randomized, controlled trial will also be needed to assess if the incidence of COPD exacerbations is altered by bronchial valve treatment. The annual rate of exacerbations in this study calculates to 1.05/year, which falls between the treatment and control group rates (0.85 and 1.13 ) in the TORCH trial, although that study enrolled patients with more moderate COPD (mean FEV1 44% of predicted) [37]. The exacerbation rate reported in the NETT control group was 0.37/year, but this only included COPD exacerbations requiring hospitalization [38]. Using a similar criterion, the rate in this study was 0.46/year; therefore the COPD exacerbation rate is probably not increased with bronchial valve treatment compared to the published literature. Another limitation of this trial is the loss of data secondary to patient withdrawals. Although our trial withdrawals were less than seen in other COPD trials [28], withdrawals are unavoidable when working with patients with severe disease and may bias long-term results.

Pilot trials have also been done with another bronchial valve and results have been published in a summary report [39]. The investigators in this composite experience described a 90-day mortality rate of 1.02%, and that 46% of patients had clinically significant improvement in FEV1 and 55% in 6MWT 90 days after the procedure. A treatment strategy of complete lobar exclusion of a single lobe appeared to provide the greatest magnitude of benefit. Since they did not use uniform protocols, patient selection, or treatment strategies it is not possible to compare results, but the safety of the procedure was established. It may well be that the improvements in FEV1 and 6MWT seen in this non-randomized composite study may be related to the focus on complete, unilobar treatment aiming for the mechanism of action of lung volume reduction by induction of atelectasis in patients with minimal interlobar collateral ventilation. The major concern with complete lobar occlusion is an increased incidence of pneumothorax with rapid induction of atelectasis, which may mitigate the clinical benefits seen with this treatment approach. A randomized trial with that device [40] was completed in 2006 [41], but the results have not yet been published.

In summary, bilateral bronchial valve treatment is a promising treatment for severe COPD with UL-pre-dominant emphysema. We have elucidated a third mechanism of action from bronchial valve treatment: redirection of ventilation to the untreated, healthier lung parenchyma. This redirection of ventilation likely results in improved ventilation/perfusion matching by blocking ventilation to the most diseased lung. This mechanism, similar to reduction in dynamic hyperinflation, is not dependent on lobar atelectasis with the risk of pneumothorax. The primary outcome goal of safety was demonstrated in this trial, and the overall safety profile compares favorably to LVRS. Bronchial valve treatment of severe emphysema needs to be studied further, but may represent another treatment option for the large number of patients worldwide with this debilitating disease.

Acknowledgments

IBV Valve US Pilot Trial Research Team (in alphabetical order by institution): Cedars-Medical Center, Los Angeles, Calif.: Robert McKenna, MD (principal investigator); Zab Mohsenifar, MD (co-principal investigator), and Carol Geaga, RN (principal clinical coordinator); Cleveland Clinic Foundation (CCF), Cleveland, Ohio: Atul Mehta, MD (principal investigator); Thomas Gildea, MD (co-principal investigator); Yvonne Meli, RN (principal clinical coordinator); Michael Machuzak, MD, and Sudish Murthy, MD; Columbia University Medical Center New York, N.Y.: Roger Maxfield, MD (principal investigator); Mark Ginsburg, MD (co-principal investigator); Fran Brogan (principal clinical coordinator); Angela Di Mango, MD; Bryon Thomashow, MD; Chun Yip, MD; Joshua Sonett, MD, and Patricia Jellen, RN; Duke University Medical Center, Durham, N.C.: Momen Wahidi, MD (principal investigator); Thomas D’Amico, MD (co-principal investigator); Linda S. Brown (principal clinical coordinator), and John Davies, MA, RRT; Indiana University Hospital, Indianapolis, Ind.: Praveen Mathur, MD (principal investigator); Francis Sheski, MD (co-principal investigator); Kathleen Keller, RN (principal clinical coordinator), and Annette Hempfling, RN; North Shore-Long Island Jewish Health System, Manhasset, N.Y.: David Ost, MD (principal investigator); Talwar Arunabh, MD (co-principal investigator); Romona Ramdeo, RN (principal clinical coordinator), and Shirley Lilavois, RN; Ohio State University, Columbus, Ohio: Philip Diaz, MD (principal investigator); Patrick Ross, MD (co-principal investigator); Mahasti Rittinger, RCP, RTP (principal clinical coordinator); Abbas El-Sayed Abbas, MD; Bonnie Massey; Janice Drake, CRTT, CCRP; Maria Lucarelli, MD; Nitin Bhatt, MD; Rachael Compton, and Shaheen Islam, MD; University of Alabama at Birmingham, Birmingham, Ala.: Robert Cerfio, MD (principal investigator); Sara Pereira MD, (co-principal investigator); Jeana Alexander, RN, BSN, (principal clinical coordinator); Ayesha Bryant; Chad Miller, MD; Keith Willie, MD, and Sandra Calloway; University of Pennsylvania Medical Center, Philadelphia, Pa.: Daniel Sierman, MD (principal investigator); Ali Musani, MD (co-principal investigator); Barbara Finkel, MSN, RN, CCRC (principal clinical coordinator); Andrew Haas, MD; Colin Gillespie, MD; David Lipson, MD; Michael Machuzak, MD; Michael Sims, MD, and Steven LeH, MD; University of Virginia Health System, Charlottesville, Va.: Jonathon Truwit, MD (principal investigator); Yun Michael Shim, MD (co-principal investigator);
We thank the University of British Columbia for CT review and quantitative analyses, and Harvey O. Coxson, PhD, Paola V. Nasute Fauerbach, MD, Claudine Storness-Bliss, Sebastian Cogens, and Nestor L. Müller, MD. We also thank Yi-Jing Duh, PhD, for statistical computations, and Linda Rismondo, Bill Sirokman and Clint Finger for data compilation.

References


Sterman et al.


